Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients

• Authors: Marcin Dziedzic , Ewelina Orlowska , Kinga Gawel , Magdalena Zawadzka , Anna Bednarek-Skublewska , Janusz Solski
• Languages of publication: EN

Abstracts

EN

The aim of the study was to assess plasma concentration of catecholamines and asymmetric dimethyl arginine levels and a possible relationship to predict the mortality rates among hemodialysis patients. The study population comprised 27 subjects, aged 65-70 years. Each patient underwent dialysis thrice a week. Furthermore, the median duration of hemodialysis was 3.5 years. Based on the conducted research, it can be concluded that the concentrations of adrenaline and the level of asymmetric dimethylarginine have predictive value of mortality among hemodialysis patients. Of note, lowering plasma asymmetric dimethylarginine concentration may represent therapeutic target for prevention of progressive renal damage.

Keywords

EN

catecholamines; asymmetric dimethylarginine; hemodialysis; renal failure

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2014
• Volume: 27
• Issue: 1
• Pages: 37-40

Dates

published

1 - 6 - 2014

received

13 - 2 - 2014

online

30 - 5 - 2014

accepted

6 - 3 - 2014

Contributors

author

Marcin Dziedzic

• Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

author

Ewelina Orlowska

• Department of Nephrology and Hypertension, Provincial Hospital of Lublin, Poland

author

Kinga Gawel

• Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Poland

author

Magdalena Zawadzka

• Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

author

Anna Bednarek-Skublewska

• Department of Nephrology, Medical University of Lublin, Poland

author

Janusz Solski

• Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

References

• 1. Agarwal R. et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med., 115, 291, 2003.[Crossref]
• 2. Aldamiz-Echevarria L., Andrade F.: Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int. J. Mol. Sci.,13, 11288, 2012.[Crossref][WoS]
• 3. Alsagaff M.Y. et al.: Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J. Int. Med. Res., 40, 340, 2012.[WoS][Crossref]
• 4. Arici M., Walls J.: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int., 59, 407, 2001.[Crossref]
• 5. Bassareo P.P. et al.: Urinary NGAL and hematic ADMA levels: an early sign of cardio-renal syndrome in young adults born preterm? J. Matern. Fetal Neonatal Med., 26, 80, 2013.
• 6. Bassareo P.P. et al.: Could ADMA levels in young adults born preterm predict an early endothelial dysfunction? Int. J. Cardiol., 159, 217, 2012.[WoS]
• 7. De Jager D.J. et al.: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA, 302, 1782, 2009.
• 8. Goonasekera C.D. et al.: Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens., 15, 901, 1997.[Crossref]
• 9. Guerin A, Pannier B, London G.: Atherosclerosis versus arterial stiffness in advanced renal failure. Adv. Cardiol.,44, 187, 2007.[Crossref]
• 10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 39, 1, 2002.
• 11. Kielstein J.T. et al.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc.Nephrol., 13, 170, 2002.
• 12. Kielstein J.T. et al.: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol., 10, 594, 1999.
• 13. Kielstein J.T. et al.: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press. Res., 27, 143, 2004.
• 14. Koch M. et al.: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant., 12, 1187, 1997.[Crossref]
• 15. Luyckx V.A., Brenner B.M. Low birth weight, nephron number and kidney disease. Kidney Int., 97, 68, 2005.[Crossref]
• 16. Mallamaci F. et al.: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol., 15, 435, 2004.[Crossref]
• 17. Nakayama Y. et al.: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int., 9, 1, 2013.[WoS]
• 18. Perticone F. et al.: Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol., 142, 236, 2010.[WoS]
• 19. Raptis V., Kapoulas S., Grekas D.: Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton), 18, 11, 2013.[Crossref][WoS]
• 20. Rocha M.S. et al.: Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency. Atherosclerosis, 222, 509, 2012.[WoS]
• 21. Rodriguez M.M. et al.: Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr. Nephrol., 20, 945, 2005.[Crossref]
• 22. Rutkowski B. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2009. Drukonsul, Gdańsk 2010.
• 23. Sarnak M.J., Levey A.S.: Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J. Thromb. Thrombolysis, 10, 169, 2000.[Crossref]
• 24. Schwarz P. et al.: Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ. Res., 77, 841, 1995.[Crossref]
• 25. Sesti G. et al.: A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with chronic kidney disease.Atherosclerosis, 231, 141, 2013.[WoS]
• 26. Sibal L. et al.: The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol.Rev., 6, 82, 2010.[Crossref]
• 27. Sydow K. et al.: Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin. Chem., 56, 111, 2010.[WoS]
• 28. Tripepi G. et al.: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients.Clin. J. Am. Soc. Nephrol., 6, 1714, 2011.[WoS][Crossref]
• 29. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.
• 30. Ueda S. et al.: Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology, 12, 582, 2007.[Crossref][WoS]
• 31. Wilcken D.E. et al.: Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Mol. Genet. Metab., 91, 309, 2007.[WoS][Crossref]
• 32. Zoccali C. et al.: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am.Soc. Nephrol., 13, 490, 2002.
• 33. Zoccali C. et al:. Inflammation is associated with carotid atherosclerosis in dialysis patients. J. Hypertens., 18, 1207, 2000.[Crossref]

Identifiers

DOI

10.2478/cipms-2014-0010